Dr. Stock on the Optimal Use of Radium-223 in mCRPC
Richard G. Stock, MD, senior faculty, Radiation Oncology, Mount Sinai Hospital, discusses the optimal use of radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer.
Richard G. Stock, MD, senior faculty, Radiation Oncology, Mount Sinai Hospital, discusses the optimal use of radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Radium-223 has been shown to affect overall survival in patients with mCRPC who have progressive disease and bone metastases, Stock explains. It has been mainly used in later lines of therapy; however, Stock envisions that this treatment could have a role in earlier settings.
The mechanism of action of radium-223 is to target the bones metastases. This is a different approach compared with external-beam radiation therapy, which delivers photon therapy to a local site, Stock adds.
